VistaGen Therapeutics, Inc. (VSTA) Joins the Cardiac ResearcVistaGen Therapeutics, Inc. (VSTA) Joins the Cardiac Research Safety Consortium
Today, VistaGen Therapeutics announced its membership in the Cardiac Research Safety Consortium, a public-private partnership launched in 2006 through an FDA Critical Path Initiative Memorandum of Understanding with Duke University. The consortium aims to support research efforts that evaluate the cardiac safety of medical products, drawing upon input from stakeholders from across industrial, academic, and governmental sectors for data sharing and expertise.
VistaGen Therapeutics is the creator of CardioSafe 3D™, a novel in vitro bioassay system capable of predicting the cardiac effects, both toxic and non-toxic, of small molecule drug candidates with greater speed and precision than alternative, often-used safety models in drug development. That is inclusive of animal models and cellular assays that use primary, immortalized, or transformed cells. VistaGen Therapeutics incorporates use of mature, functional heart cells differentiated from human pluripotent stem cells for its revolutionary in vitro bioassay system.
The company’s CardioSafe 3D™is the central component of the company’s groundbreaking stem cell technology platform, Human Clinical Trials in a Test Tube™. With its ability to detect unexpected heart and liver safety issues in drug candidates, the stem cell technology is said to have tremendous potential for remedying widespread drug discovery and development crises within the U.S. pharmaceutical industry. VistaGen Therapeutics will be extending its expertise in cardiac safety for advancement of research efforts in the consortium.
“We look forward to partnering with the pharmaceutical, biotechnology, academic, and regulatory members of the Cardiac Safety Research Consortium, and contributing our expertise to support rapid advancement of our understanding of cardiac safety. Cardiac safety, especially identifying proarrhythmic safety concerns of new drug candidates prior to human studies, drives our internal efforts every day, and we welcome the opportunity to participate in this innovative process with the consortium,” said Ralph Snodgrass, Ph.D., VistaGen’s President and Chief Scientific Officer.
“VistaGen shares our commitment to improving cardiac safety of new medical products, and its membership will strengthen CSRC,” commented Mitchell W. Krucoff, MD, FACC, Professor of Medicine at Duke University and CSRC Co-Chairperson. “We look forward to a productive, long-term relationship with VistaGen.”
For more information about VistaGen Therapeutics and its biotechnological initiatives, please visit: www.vistagen.com
Please read full disclaimers at https://disclaimer.missionir.com